Quo vadis Rossova operace?

Jan Vojáček, Jaroslav Špatenka

Interv Akut Kardiol 2012; 11(5-6): 175-176  

Strach z výsledků vyšetření aneb Čeho a proč se vlastně bojíme?

Mgr. Roman Pešek

Interv Akut Kardiol 2012; 11(5-6): 171  

Influence of entry anemia on long-term mortality of patients admitted with acute heart failure

Roman Miklík, Marián Felšöci, Jiří Pařenica, Jiří Jarkovský, Kateřina Hořáková, Jindřich Špinar

Interv Akut Kardiol 2012; 11(5-6): 177-182  

Aim of the study: In patients admitted with acute heart failure (AHF) to evaluate a relationship between entry hemoglobin (Hb) level and variables that are known to influence a long-term mortality in patients admitted with acute heart failure (AHF). To investigate a long-term mortality and describe differencies in impact of anemia on survival of all patients with AHF and particularly for the most frequent etiologies – acute coronary syndrome (ACS) presenting as STEMI (n = 325) and nonSTEMI (n = 207), decompensated ischemic heart disease (IHD, n = 209) and dilated cardiomyopathy (CMP, n = 88). Results: 1-year mortality of 1044 AHF patients...

Integrity - a new sinusoid coronary stent technology

Roman Štípal, Jiří Ostřanský, David Richter, Marcela Škvařilová, David Vindiš

Interv Akut Kardiol 2012; 11(5-6): 183-186  

Continuous sinusoid technology is the result of more than 10 years of research and development. This technology is applied by Integrity stent which demonstrates better flexibility, deliverability, conformity, radial strength and trackability in comparison with previous Driver Sprint system and some other competitors. Integrity system is used by standard as well as by drug eluting stents.

ECG monitoring after ablation for atrial fibrillation

Jan Chovančík, Veronika Bulková, Martin Fiala

Interv Akut Kardiol 2012; 11(5-6): 187-191  

Cessation of anticoagulation therapy is one of the goals of catheter ablation for atrial fibrillation (AF). Asymptomatic AF recurrences may, however, imperil an apparently cured patient by thromboembolic complication. Asymptomatic AF recurrences after catheter ablation have been described in 2 % to more than 50 % of the patients. They may be detected by longer-term ECG monitoring; however, a comfortable and clinically applicable recorder of continuous ECG is not currently available. This overview aims at analyzing the clinical impact of asymptomatic AF recurrences, and options to detect it by external or implantable ECG recorders.

Pompe disease as seen by a pediatric cardiologist

Veronika Stará

Interv Akut Kardiol 2012; 11(5-6): 192-195  

Pompe disease is rare, autosomal recessive disorder, caused by deficiency of enzyme acid-alpha-glucosidase that plays important role in glycogen metabolism. The lack of enzyme leads to abnormal glycogen storage in different tissues. Skeletal and cardiac muscles are predominantly affected, though accumulation in liver and endothelial cells is also common. The clinical presentation of disease varies by age – in infancy is characterized by severe generalized hypotonia, failure to thrive and hypertrophic cardiomyopathy, in some cases accompanied with obstruction of left ventricular outflow tract or with different arrhythmias. In childhood...

Warfarin and dual antiplatelet therapy for recurrent acute myocardial infarction with coronary artery ectasia

Ivo Varvařovský, Petr Vojtíšek, Jan Matějka, Bořivoj Korbel

Interv Akut Kardiol 2012; 11(5-6): 211-214  

Recurrence of acute myocardial infarction within 24 hours of direct coronary angioplasty was managed with thrombus aspiration and repeated dilatation of the original stent. Ectatic coronary artery dilatation around the original stent was suspected and confirmed by intracoronary ultrasound and CT coronary angiography. Due to coronary artery ectasia, the patient was, in addition to common dual antiplatelet therapy, also treated with oral anticoagulation therapy for a period of six weeks after his second direct angioplasty. He experienced no bleeding complications during that period and is currently free of clinical signs and receiving standard...

Patient with severe heart failure on initial out-patient presentation; central role of echocardiography

Antonín Novák, Josef Jakabčin, Jiří Herman, Andrej Kupec, Marian Bystroň, Radim Špaček, Milena Kubičková, Martin Kvašňák, Pavel Červinka

Interv Akut Kardiol 2012; 11(5-6): 216-218  

Authors present two cases of patients who came to the hospital for the first out-patient examination with severe heart failure, dilatated left ventricle and a very low ejection fraction. After the start of the therapy, the next diagnostic step was a coronary angiography. The results of coronary the possibility of coronary revascularization (1). Echocardiography plays the central role in the next controls (2). In case of resting heart rate is more than 70 per minute, ivabradine administration is indicated to established pharmacotherapy of the heart failure (3, 4). The improvement of the ejection fraction helps the patients to improve quality...

Coming soon: prasugrel, ticagrelor and STEMI

Ivo Varvařovský

Interv Akut Kardiol 2012; 11(5-6): 197-200  

Treatment with prasugrel and ticagrelor can decrease substantially ischemic complications of acute coronary syndromes, but the rise in major bleeding complications is not negligible. However, in STEMI patients the positive effect of prasugrel and ticagrelor is more expressed, and bleeding complications are not different from conventional therapy. This treatment may become first-line treatment of STEMI patients during primary coronary angioplasty.

Significance of pharmacological intervention for heart rate in treating cardiovascular disease

Jan Bultas

Interv Akut Kardiol 2012; 11(5-6): 202-210  

Heart rate is an independent factor affecting ischaemic load in patients with angina pectoris and the rate of cardiovascular events in patients with chronic heart failure. The dependence of all-cause as well as cardiovascular mortality on baseline heart rate has been documented in long-term monitoring of healthy population. During pharmacological intervention as part of prophylaxis for myocardial ischaemia in patients with angina pectoris, a reduction in ischaemic load has been documented for both treatment with beta blockers and treatment with ivabradine. Whether the rates of cardiovascular events and mortality are also favourably affected...

Zpráva z kongresu Evropské společnosti pro hypertenzi: 22nd European Meeting on Hypertension and Cardiovascular Protection (ESH) 2012

Filip Málek

Interv Akut Kardiol 2012; 11(5-6): 219-221  

Zpráva ze sympozia Invazivní kardiologie v Českém ráji, Hrubá Skála 2012

Jan Vojáček

Interv Akut Kardiol 2012; 11(5-6): 222  

Zpráva z Evropského kardiologického sjezdu ESC, Mnichov 2012

Jan Vojáček

Interv Akut Kardiol 2012; 11(5-6): 223-224  

Doc. MUDr. Jan Harrer, CSc., šedesátiletý

Jan Vojáček, Jan Dominik a spolupracovníci

Interv Akut Kardiol 2012; 11(5-6): 231-232  

BioMimeTM Sirolimus eluting coronary stent

BioMimeTM Sirolimus uvolňující koronární stent přichází s novou myšlenkou biomimikrického konceptu stentu.Stent je vystavěn na ultra-

Interv Akut Kardiol 2012; 11(5-6): 226-228  

BioMimeTM Sirolimus eluting coronary stent comes with a new idea of taking stents towards a biomimicry concept. The stent is built on an ultra-thin strut thickness (65 μm) cobalt chromium stent platform using an intelligent hybrid system of open and closed cells, allowing for a morphology-mediated expansion, while employing a well-known antiproliferant, Sirolimus, that is eluted from a biodegradable copolymer within 30 days and provides high coating integrity and a low coating thickness of up to 2 μm. The resultant stent demonstrates nearly 100% endothelialization in 30-day preclinical models and low MACE rates (< 5%) in clinical...